Skip to main content

Table 1 In vivo efficacy of TY-011 against human MGC-803 xenograft

From: Antitumor activity of TY-011 against gastric cancer by inhibiting Aurora A, Aurora B and VEGFR2 kinases

Compound

Body weight (g)

Tumor volume (mm3)

T/C (%)

TGI (%)

Tumor weight (g)

Inhibition rate (%)

Start

End

Start

End

Control

22.1 ± 0.2

22.6 ± 0.2

190.4 ± 6.2

783.7 ± 22.7

/

/

0.79 ± 0.07

/

TY-011 (3 mg/kg)

20.8 ± 0.1

21.8 ± 0.1

192.8 ± 7.1

433.6 ± 16.2***

54.55

59.41

0.28 ± 0.02***

64.9

TY-011 (6 mg/kg)

20.9 ± 0.1

20.3 ± 0.2

191.2 ± 6.2

168.8 ± 7.1***

21.82

103.77

0.10 ± 0.01***

87.7

TY-011 (9 mg/kg)

21.4 ± 0.1

21.7 ± 0.1

189.0 ± 4.9

111.4 ± 3.6***

14.53

113.09

0.09 ± 0.01***

89.0

Irinotecan (50 mg/kg)

21.2 ± 0.2

21.4 ± 0.2

191.7 ± 6.7

59.3 ± 6.5***

8.04

122.31

0.03 ± 0.01***

96.2

  1. The body weight, tumor volume, T/C values, TGI, tumor weight, and inhibition rate were used to evaluate the tumor response to TY-011 treatment
  2. Data presented are the mean ± SEM. ***p < 0.001 vs. control